In this study, we have identified a novel antagonist ligand of GPER, namely C4PY, which exhibits an inhibitory action on GPER-activated signaling, including the repression of both ERK and Akt phosphorylation, gene transcription, and cell proliferation and migration in breast cancer cells and in CAFs. Here, MAPK1 is linked to breast carcinoma.